Connection

Robert Harrington to Acute Coronary Syndrome

Back to Details
This is a "connection" page, showing publications Robert Harrington has written about Acute Coronary Syndrome.
Robert Harrington
Connection Strength
17.505
Acute Coronary Syndrome
  1. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022 Feb 15; 327(7):662-675.
    View in: PubMed
    Score: 0.675
  2. Antithrombotic Therapy after Acute Coronary Syndromes. Reply. N Engl J Med. 2021 05 13; 384(19):1873-1874.
    View in: PubMed
    Score: 0.640
  3. Management of Antithrombotic Therapy after Acute Coronary Syndromes. N Engl J Med. 2021 Feb 04; 384(5):452-460.
    View in: PubMed
    Score: 0.628
  4. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). Am J Cardiol. 2015 May 15; 115(10):1325-32.
    View in: PubMed
    Score: 0.416
  5. Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. Clin Cardiol. 2014 Jun; 37(6):337-42.
    View in: PubMed
    Score: 0.388
  6. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol. 2014 Mar 15; 113(6):936-44.
    View in: PubMed
    Score: 0.384
  7. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. Int J Cardiol. 2014 Jan 01; 170(3):e59-62.
    View in: PubMed
    Score: 0.381
  8. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. Eur Heart J Acute Cardiovasc Care. 2013 Sep; 2(3):246-55.
    View in: PubMed
    Score: 0.376
  9. Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. Int J Cardiol. 2013 Jul 31; 167(2):548-54.
    View in: PubMed
    Score: 0.338
  10. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):448-58.
    View in: PubMed
    Score: 0.323
  11. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009 Dec 10; 361(24):2318-29.
    View in: PubMed
    Score: 0.290
  12. A new generation of antiplatelet agents. Curr Opin Cardiol. 2009 Jul; 24(4):307-12.
    View in: PubMed
    Score: 0.281
  13. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):670S-707S.
    View in: PubMed
    Score: 0.261
  14. International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2008 Jan 01; 101(1):25-29.
    View in: PubMed
    Score: 0.252
  15. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation. 2023 01 03; 147(1):8-19.
    View in: PubMed
    Score: 0.177
  16. Biomarker-Based Prediction of Recurrent?Ischemic Events in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2022 11 01; 80(18):1735-1747.
    View in: PubMed
    Score: 0.177
  17. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. J Clin Lipidol. 2022 Sep-Oct; 16(5):747-756.
    View in: PubMed
    Score: 0.175
  18. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation. 2022 Aug 30; 146(9):657-672.
    View in: PubMed
    Score: 0.173
  19. Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. Eur Heart J Acute Cardiovasc Care. 2022 Jun 07; 11(4):336-349.
    View in: PubMed
    Score: 0.172
  20. Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial. Am J Med. 2022 07; 135(7):915-918.
    View in: PubMed
    Score: 0.170
  21. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. J Am Coll Cardiol. 2020 07 14; 76(2):162-171.
    View in: PubMed
    Score: 0.151
  22. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2020 05 12; 75(18):2297-2308.
    View in: PubMed
    Score: 0.149
  23. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute?Coronary Syndrome. J Am Coll Cardiol. 2020 01 21; 75(2):133-144.
    View in: PubMed
    Score: 0.146
  24. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. J Am Coll Cardiol. 2019 09 03; 74(9):1177-1186.
    View in: PubMed
    Score: 0.142
  25. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. 2019 11 05; 140(19):1578-1589.
    View in: PubMed
    Score: 0.142
  26. Effect of Alirocumab on Mortality After Acute Coronary Syndromes. Circulation. 2019 07 09; 140(2):103-112.
    View in: PubMed
    Score: 0.140
  27. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary?Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 09 03; 74(9):1167-1176.
    View in: PubMed
    Score: 0.138
  28. Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. J Am Heart Assoc. 2018 12 18; 7(24):e009609.
    View in: PubMed
    Score: 0.136
  29. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019 02 05; 73(4):387-396.
    View in: PubMed
    Score: 0.135
  30. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 11 29; 379(22):2097-2107.
    View in: PubMed
    Score: 0.134
  31. Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2018 05 14; 11(9):856-864.
    View in: PubMed
    Score: 0.130
  32. Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2018 02; 196:28-35.
    View in: PubMed
    Score: 0.125
  33. Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. Am J Med. 2017 10; 130(10):1170-1176.
    View in: PubMed
    Score: 0.120
  34. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017 Mar 14; 38(11):804-810.
    View in: PubMed
    Score: 0.120
  35. Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Am Heart J. 2017 May; 187:194-203.
    View in: PubMed
    Score: 0.119
  36. Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS. Int J Cardiol. 2017 Apr 01; 232:264-270.
    View in: PubMed
    Score: 0.118
  37. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem. 2017 Feb; 63(2):573-584.
    View in: PubMed
    Score: 0.118
  38. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute?Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. JACC Cardiovasc Interv. 2016 09 26; 9(18):1905-13.
    View in: PubMed
    Score: 0.116
  39. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. Eur Heart J Acute Cardiovasc Care. 2017 Mar; 6(2):155-163.
    View in: PubMed
    Score: 0.116
  40. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. Eur Heart J Acute Cardiovasc Care. 2018 Mar; 7(2):158-165.
    View in: PubMed
    Score: 0.115
  41. Radial access in patients with acute coronary syndrome without persistent ST-segment elevation: Systematic review, collaborative meta-analysis, and meta-regression. Int J Cardiol. 2016 Nov 01; 222:1031-1039.
    View in: PubMed
    Score: 0.115
  42. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2016 08; 178:176-84.
    View in: PubMed
    Score: 0.114
  43. Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. J Am Coll Cardiol. 2016 May 10; 67(18):2135-2144.
    View in: PubMed
    Score: 0.113
  44. Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy. Circ Cardiovasc Interv. 2016 May; 9(5):e003114.
    View in: PubMed
    Score: 0.113
  45. Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. Am Heart J. 2016 Aug; 178:1-8.
    View in: PubMed
    Score: 0.113
  46. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8.
    View in: PubMed
    Score: 0.113
  47. Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. JAMA Cardiol. 2016 04 01; 1(1):73-9.
    View in: PubMed
    Score: 0.112
  48. Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. Circulation. 2016 Apr 19; 133(16):1560-73.
    View in: PubMed
    Score: 0.112
  49. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Catheter Cardiovasc Interv. 2016 Aug; 88(2):163-73.
    View in: PubMed
    Score: 0.110
  50. Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery. J Am Heart Assoc. 2015 Dec 15; 4(12).
    View in: PubMed
    Score: 0.110
  51. Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. Int J Cardiol. 2016 Jan 15; 203:708-13.
    View in: PubMed
    Score: 0.109
  52. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention. 2015 Nov; 11(7):737-45.
    View in: PubMed
    Score: 0.109
  53. Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. Circ Cardiovasc Qual Outcomes. 2015 Jul; 8(4):357-67.
    View in: PubMed
    Score: 0.107
  54. Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. Heart. 2015 Sep; 101(18):1475-84.
    View in: PubMed
    Score: 0.106
  55. Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc. 2015 Jun 18; 4(6):e001512.
    View in: PubMed
    Score: 0.106
  56. Magnitude of troponin elevation and long-term clinical outcomes in acute coronary syndrome patients treated with and without revascularization. Circ Cardiovasc Interv. 2015 Jun; 8(6):e002314.
    View in: PubMed
    Score: 0.106
  57. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study. J Am Coll Cardiol. 2015 Feb 10; 65(5):465-76.
    View in: PubMed
    Score: 0.104
  58. Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. Am Heart J. 2015 Apr; 169(4):531-8.
    View in: PubMed
    Score: 0.103
  59. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Am Heart J. 2014 Dec; 168(6):869-77.e1.
    View in: PubMed
    Score: 0.101
  60. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9.
    View in: PubMed
    Score: 0.100
  61. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). Am Heart J. 2014 Oct; 168(4):588-96.
    View in: PubMed
    Score: 0.099
  62. No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. Int J Cardiol. 2014 Sep; 176(1):300-2.
    View in: PubMed
    Score: 0.099
  63. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014 Sep 01; 114(5):665-73.
    View in: PubMed
    Score: 0.099
  64. Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial". Circulation. 2014 May 13; 129(19):e494-5.
    View in: PubMed
    Score: 0.099
  65. Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes. Am Heart J. 2014 Aug; 168(2):182-8.e1.
    View in: PubMed
    Score: 0.098
  66. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014 Aug 14; 35(31):2083-93.
    View in: PubMed
    Score: 0.098
  67. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Eur Heart J Acute Cardiovasc Care. 2014 Sep; 3(3):246-56.
    View in: PubMed
    Score: 0.097
  68. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2014 Apr 22; 63(15):1493-9.
    View in: PubMed
    Score: 0.097
  69. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014 Mar 25; 63(11):1048-57.
    View in: PubMed
    Score: 0.095
  70. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014 Jan 21; 129(3):293-303.
    View in: PubMed
    Score: 0.095
  71. Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. Am Heart J. 2013 Oct; 166(4):723-8.
    View in: PubMed
    Score: 0.094
  72. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013 Sep 03; 128(10):1055-65.
    View in: PubMed
    Score: 0.093
  73. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. Am Heart J. 2013 Sep; 166(3):466-73.
    View in: PubMed
    Score: 0.093
  74. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv. 2013 Jul; 6(7):671-83.
    View in: PubMed
    Score: 0.093
  75. Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke. 2013 Aug; 44(8):e95-6.
    View in: PubMed
    Score: 0.093
  76. Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. Am J Med. 2013 Aug; 126(8):723-729.e1.
    View in: PubMed
    Score: 0.093
  77. Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. JACC Heart Fail. 2013 Jun; 1(3):223-9.
    View in: PubMed
    Score: 0.092
  78. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Crit Pathw Cardiol. 2013 Jun; 12(2):65-105.
    View in: PubMed
    Score: 0.092
  79. Response to letter regarding article, ?sustained ventricular tachycardia and ventricular fibrillation complicating non?ST-segment elevation acute coronary syndromes?. Circulation. 2013 May 21; 127(20):e634.
    View in: PubMed
    Score: 0.092
  80. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. J Am Coll Cardiol. 2013 Jul 16; 62(3):242-251.
    View in: PubMed
    Score: 0.092
  81. Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients. Eur Heart J Acute Cardiovasc Care. 2014 Mar; 3(1):37-45.
    View in: PubMed
    Score: 0.092
  82. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May; 44(5):1477-9.
    View in: PubMed
    Score: 0.091
  83. Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. J Am Coll Cardiol. 2013 Apr 02; 61(13):1461-3.
    View in: PubMed
    Score: 0.091
  84. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA?CER) trial. Eur Heart J. 2013 Jun; 34(23):1723-31.
    View in: PubMed
    Score: 0.091
  85. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial. Heart. 2013 Sep; 99(17):1282-7.
    View in: PubMed
    Score: 0.091
  86. Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategy. Am Heart J. 2013 Apr; 165(4):583-590.e1.
    View in: PubMed
    Score: 0.091
  87. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013 Jun; 165(6):918-925.e2.
    View in: PubMed
    Score: 0.090
  88. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards). Circulation. 2013 Mar 05; 127(9):1052-89.
    View in: PubMed
    Score: 0.090
  89. 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on clinical data standards (writing committee to develop acute coronary syndromes and coronary artery disease clinical data standards). J Am Coll Cardiol. 2013 Mar 05; 61(9):992-1025.
    View in: PubMed
    Score: 0.090
  90. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. JACC Cardiovasc Interv. 2012 Sep; 5(9):927-35.
    View in: PubMed
    Score: 0.088
  91. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. Int J Cardiol. 2013 Sep 10; 167(6):2580-7.
    View in: PubMed
    Score: 0.087
  92. Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes. Circulation. 2012 Jul 03; 126(1):41-9.
    View in: PubMed
    Score: 0.086
  93. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial. Circ Cardiovasc Qual Outcomes. 2012 Mar 01; 5(2):205-13.
    View in: PubMed
    Score: 0.085
  94. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation. 2012 Jan 24; 125(3):514-21.
    View in: PubMed
    Score: 0.083
  95. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011 Dec; 32(23):2933-44.
    View in: PubMed
    Score: 0.083
  96. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012 Jan 05; 366(1):20-33.
    View in: PubMed
    Score: 0.083
  97. Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. Am Heart J. 2011 Nov; 162(5):884-892.e1.
    View in: PubMed
    Score: 0.083
  98. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol. 2011 Dec 01; 108(11):1542-6.
    View in: PubMed
    Score: 0.082
  99. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011 Dec; 32(23):2945-53.
    View in: PubMed
    Score: 0.081
  100. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25; 365(8):699-708.
    View in: PubMed
    Score: 0.081
  101. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011 Jun 17; 342:d3527.
    View in: PubMed
    Score: 0.081
  102. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011 May 10; 57(19):1908-16.
    View in: PubMed
    Score: 0.080
  103. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial. Circulation. 2011 Feb 22; 123(7):722-30.
    View in: PubMed
    Score: 0.079
  104. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011 Feb 08; 57(6):672-84.
    View in: PubMed
    Score: 0.078
  105. Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. Am Heart J. 2010 Dec; 160(6):1056-64, 1064.e2.
    View in: PubMed
    Score: 0.078
  106. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010 Nov 23; 122(21):2131-41.
    View in: PubMed
    Score: 0.077
  107. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010 Sep 14; 122(11):1056-67.
    View in: PubMed
    Score: 0.076
  108. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010 Nov; 104(5):976-83.
    View in: PubMed
    Score: 0.076
  109. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med. 2010 Feb; 123(2):134-40.
    View in: PubMed
    Score: 0.073
  110. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010 Jan 23; 375(9711):283-93.
    View in: PubMed
    Score: 0.073
  111. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10; 361(24):2330-41.
    View in: PubMed
    Score: 0.073
  112. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. Am Heart J. 2009 Dec; 158(6):881-886.e1.
    View in: PubMed
    Score: 0.072
  113. Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). Am J Cardiol. 2009 Nov 15; 104(10):1330-5.
    View in: PubMed
    Score: 0.071
  114. Antithrombotics in acute coronary syndromes. J Am Coll Cardiol. 2009 Sep 08; 54(11):969-84.
    View in: PubMed
    Score: 0.071
  115. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10; 361(11):1045-57.
    View in: PubMed
    Score: 0.071
  116. Sex differences in mortality following acute coronary syndromes. JAMA. 2009 Aug 26; 302(8):874-82.
    View in: PubMed
    Score: 0.071
  117. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 09; 119(22):2877-85.
    View in: PubMed
    Score: 0.070
  118. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol. 2010 Sep 24; 144(1):36-41.
    View in: PubMed
    Score: 0.070
  119. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009 May 12; 119(18):2454-62.
    View in: PubMed
    Score: 0.069
  120. Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. Am Heart J. 2009 Apr; 157(4):716-23.
    View in: PubMed
    Score: 0.069
  121. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202.
    View in: PubMed
    Score: 0.069
  122. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009 May 21; 360(21):2176-90.
    View in: PubMed
    Score: 0.069
  123. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation. 2009 Feb 03; 119(4):597-605.
    View in: PubMed
    Score: 0.068
  124. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008 Nov; 156(5):826-32.
    View in: PubMed
    Score: 0.066
  125. Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. Am Heart J. 2008 Jul; 156(1):177-84.
    View in: PubMed
    Score: 0.065
  126. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008 Mar 11; 51(10):991-6.
    View in: PubMed
    Score: 0.064
  127. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008 Jun; 155(6):1047-53.
    View in: PubMed
    Score: 0.064
  128. Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. Clin Cardiol. 2008 Mar; 31(3):125-9.
    View in: PubMed
    Score: 0.064
  129. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008 Feb; 155(2):369-74.
    View in: PubMed
    Score: 0.063
  130. Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007 Dec 04; 116(23):2669-77.
    View in: PubMed
    Score: 0.063
  131. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol. 2007 Nov 06; 50(19):1844-51.
    View in: PubMed
    Score: 0.063
  132. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007 May; 28(10):1193-204.
    View in: PubMed
    Score: 0.060
  133. Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY?OUTCOMES. J Am Coll Cardiol. 2020 02 04; 75(4):448-451.
    View in: PubMed
    Score: 0.037
  134. Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. Blood Cells Mol Dis. 2018 09; 72:37-43.
    View in: PubMed
    Score: 0.033
  135. Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. Am Heart J. 2018 03; 197:1-8.
    View in: PubMed
    Score: 0.031
  136. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Dec 14; 382(9909):1981-92.
    View in: PubMed
    Score: 0.023
  137. Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction. Am J Cardiol. 2008 Nov 01; 102(9):1119-24.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.